Similarly, the combination of pembrolizumab, a PD-1 inhibitor, and trastuzumab, a HER2-targeted antibody used to treat breast cancer, has been associated with increased interleukin expression in female C57B1/6 mice [244,245]. Here, ERBB2 is linked to breast carcinoma.